| Patent Number |
Title Of Patent |
Date Issued |
| 6399627 |
Inhibitors of factor Xa |
June 4, 2002 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6376515 |
Benzamides and related inhibitors of factor Xa |
April 23, 2002 |
| Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful |
| 6372475 |
Cloning and characterization of a human adenylyl cyclase |
April 16, 2002 |
| A DNA sequence encoding a human adenylyl cyclase is described. The amino acid sequence of the adenylyl cyclase is also described. |
| 6369080 |
Selective factor Xa inhibitors |
April 9, 2002 |
| Novel compounds of formula I: ##STR1##including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositi |
| 6369063 |
Selective factor Xa inhibitors |
April 9, 2002 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6333321 |
Selective factor Xa inhibitors |
December 25, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6297026 |
Nucleic acids encoding the C140 receptor |
October 2, 2001 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 6291469 |
Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
September 18, 2001 |
| This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): ##STR1##wherein Q, L, A.sub.i, B.sub.j, R.sub.0, R.sub.3, R.sub.10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of |
| 6262047 |
Selective factor Xa inhibitors |
July 17, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6245743 |
Inhibitors of factor Xa |
June 12, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6228854 |
Selective factor Xa inhibitors |
May 8, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6218382 |
Selective factor Xa inhibitors |
April 17, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are usefull in vitro or in vivo for preventing or treating coagulation disorders. |
| 6211183 |
Selective factor Xa inhibitors |
April 3, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6211154 |
Ketoheterocyclic inhibitors of factor Xa |
April 3, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6210913 |
Modulation of integrin-mediated signal transduction |
April 3, 2001 |
| The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the .beta.-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin mediated signaling, methods of iden |
| 6204268 |
Selective factor Xa inhibitors |
March 20, 2001 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6197748 |
Ketoheterocyclic inhibitors of factor Xa |
March 6, 2001 |
| Ketoheterocyclic compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are usefull in vitro or in vivo for preventing or treating coagulation disorders. |
| 6197541 |
Recombinant thrombin receptors and assays using them |
March 6, 2001 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
| 6194557 |
Nucleic acid molecules encoding Bap-1 proteins |
February 27, 2001 |
| The present invention provides the amino acid and nucleotide sequence of a protein that binds to .beta.3 integrins, .alpha.IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block |
| 6194435 |
Lactams as selective factor Xa inhibitors |
February 27, 2001 |
| Novel lactams, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds of Formula I below: ##STR1##are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6133256 |
Selective factor Xa inhibitors |
October 17, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6124101 |
Recombinant thrombin receptor and related pharmaceuticals |
September 26, 2000 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
| 6117836 |
Glycosylation-mediated inhibition of factor X |
September 12, 2000 |
| Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an .alpha.2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents |
| 6083688 |
Platelet glycoprotein V gene and uses |
July 4, 2000 |
| This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with ot |
| 6069130 |
Ketoheterocyclic inhibitors of factor Xa |
May 30, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6063794 |
Selective factor Xa inhibitors |
May 16, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6063582 |
Methods of screening for compounds that interact with human P.sub.2u2 purinergic receptor |
May 16, 2000 |
| A novel subtype of the P.sub.2 -purinergic receptor, referred to as the P.sub.2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor and associated screening and |
| 6060588 |
Bap-1 proteins |
May 9, 2000 |
| The present invention provides the amino acid and nucleotide sequence of a protein that binds to .beta.3 integrins, .alpha.IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods for identifying agents that block |
| 6046169 |
Inhibitors of factor XA |
April 4, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6043212 |
Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor |
March 28, 2000 |
| Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are |
| 6024936 |
Antibody-based method of localizing activated thrombin receptors |
February 15, 2000 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
| 6022861 |
Ketoheterocyclic inhibitors of factor Xa |
February 8, 2000 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 6005089 |
Platelet glycoprotein V gene and uses |
December 21, 1999 |
| This invention relates to the glycoprotein v gene. Specifically, this invention discloses the sequence and structure of the glycoprotein v gene and the amino acid sequence of the glycoprotein v polypeptide. In addition, the evolutionary relationship of the glycoprotein v gene with ot |
| 5990079 |
Agents affecting thrombosis and hemostasis |
November 23, 1999 |
| Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilia |
| 5968902 |
Platelet aggregation inhibitors |
October 19, 1999 |
| The isolated and purified PAI from several active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formulawherein each R.sup.1 is independently H, alky |
| 5968897 |
Agents affecting thrombosis and hemostasis |
October 19, 1999 |
| Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic |
| 5958732 |
Platelet aggregation inhibitors |
September 28, 1999 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5935926 |
Platelet aggregation inhibitors |
August 10, 1999 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5919765 |
Inhibitors of factor XA |
July 6, 1999 |
| Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders. |
| 5916908 |
Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
June 29, 1999 |
| A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of the formula: ##STR1## wherein: R.sub.1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroaryl lower alkyl, 5- or 6-membered heterocy |
| 5872218 |
Human platelet-derived growth factor receptor extracellular domain antibodies |
February 16, 1999 |
| This invention provides antibodies that bind to epitopes of human platelet-derived growth factor receptor (hPDGF-R) fragments, wherein the fragments comprise one or more platelet-derived growth factor (PDGF) ligand binding regions from extracellular domains D1, D2, and D3. Also provi |
| 5871963 |
P2u2 purinergic receptor and nucleic acid encoding the receptor |
February 16, 1999 |
| A novel subtype of the P.sub.2 -purinergic receptor, referred to as the P.sub.2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the receptor and associated screening and |
| 5866681 |
Thrombin receptor antagonists |
February 2, 1999 |
| Peptide derivatives serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. The derivatives generally have the formula ##STR1## in which R.sup.1 and R.sup.3 ar |
| 5856448 |
Antibodies specifically reactive with thrombin receptor and its components |
January 5, 1999 |
| The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the |
| 5851839 |
Platelet aggregation inhibitors |
December 22, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5843897 |
Platelet aggregation inhibitors |
December 1, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
| 5837679 |
Agents affecting thrombosis and hemostasis |
November 17, 1998 |
| Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are useful in treating hemophilic |
| 5817310 |
Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
October 6, 1998 |
| The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimulated) receptor activation as indic |
| 5807828 |
Platelet aggregation inhibitors |
September 15, 1998 |
| Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds. |
| 5807825 |
Platelet aggregation inhibitors |
September 15, 1998 |
| An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samples was accomplished. The isolate |
